Company insider dossier

Kazia Therapeutics Ltd ADR insider intelligence

KZIA filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
50/100

No directional read

14/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
19 Jun 2026

Investment committee read

No directional read

The tape contains filings, but none provide enough priced common-share evidence for a directional classification.

Evidence is contextual

Evidence in favour

  • The evidence is retained for monitoring, but no broad conviction cluster is present yet.

Decision risks

  • Most filings are awards, derivatives, unpriced common shares, or other securities and remain contextual.
Conviction50No directional read
Confidence14Thin evidence
Named insiders2participating in the tape
Controlled events0directional common-share events
Acquisition value$0normalized amount
Disposal value$0normalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

15.0512.119.186.243.30
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
13.89 USD
One-week move
+10.0%
Four-week move
+2.4%
Fair-value gap
-8.4%
Trend signal
Active
Relative strength
30.2

Directional balance

Controlled event mix

0%acquisition
Acquisition events
0
Disposal events
0
Net value
$0

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

025 May
001 Jun
008 Jun
215 Jun
022 Jun
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
010 Aug

Named participants

Insider conviction by person

LEVINE, JAMES E.Chief Financial Officer500 events
RAO, SUDHAChief Scientific Officer500 events

Evidence quality

Security and transaction context

Common equity0
Equity compensation0
Options and derivatives2
Other securities0

Role architecture

Who is participating

Finance leadership1
Other executive1

Transaction evidence

Auditable KZIA filing ledger

Showing 1 to 2 of 2.

LEVINE, JAMES E.Chief Financial Officer
AcquisitionOptions and derivatives
200000 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
RAO, SUDHAChief Scientific Officer
AcquisitionOptions and derivatives
250000 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context